1-3 of 3
Gerjan de Bruin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Clinical Trials & Observations
Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla
Journal: Blood
Blood (2024) 144 (10): 1061–1068.
https://doi.org/10.1182/blood.2023023659
Published: 2024
Includes: Supplemental data
Journal Articles

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

Allard Kaptein, Gerjan de Bruin, Maaike Emmelot-van Hoek, Bas van de Kar, Anouk de Jong, Michael Gulrajani, Dennis Demont, Todd Covey, PhD, Diana Mittag, Tjeerd Barf
Journal: Blood
Blood (2018) 132 (Supplement 1): 1871.
https://doi.org/10.1182/blood-2018-99-109973
Published: 2018
Journal Articles

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Andrej Besse, Lenka Besse, Marianne Kraus, Juergen Bader, Gerjan de Bruin, Herman S Overkleeft, Christoph Driessen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5388.
https://doi.org/10.1182/blood.V130.Suppl_1.5388.5388
Published: 2017